Braveheart Bio (NASDAQ:BRVE – Get Free Report) was upgraded by research analysts at Zacks Research to a “hold” rating in a report released on Tuesday, Zacks reports.
A number of other research analysts also recently issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Braveheart Bio in a research report on Monday. They set an “overweight” rating and a $40.00 target price for the company. TD Cowen started coverage on shares of Braveheart Bio in a research note on Monday. They set a “buy” rating on the stock. Jefferies Financial Group assumed coverage on shares of Braveheart Bio in a research note on Monday. They issued a “buy” rating and a $48.00 target price for the company. Wall Street Zen raised shares of Braveheart Bio to a “hold” rating in a research report on Saturday, August 15th. Finally, The Goldman Sachs Group started coverage on Braveheart Bio in a report on Monday. They set a “buy” rating and a $48.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Braveheart Bio currently has a consensus rating of “Moderate Buy” and an average price target of $45.25.
Read Our Latest Research Report on BRVE
Braveheart Bio Stock Up 2.5%
Insider Transactions at Braveheart Bio
In related news, Director David Charles Lubner bought 55,555 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $999,990.00. Following the acquisition, the director owned 55,555 shares in the company, valued at $999,990. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Orbimed Advisors Llc bought 1,940,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $34,920,000.00. Following the transaction, the director directly owned 11,901,826 shares of the company’s stock, valued at $214,232,868. This trade represents a 19.47% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 8,751,942 shares of company stock valued at $157,534,956 in the last three months.
Braveheart Bio Company Profile
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
Featured Articles
- Five stocks we like better than Braveheart Bio
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.
